About Weidong Zhong

Dr. Zhong is a successful biotech entrepreneur, global R&D executive, and distinguished researcher with more than 25 years’ industrial experience. He has delivered over 20 small molecule and biologic drug candidates to clinical development, including marketing authorizations. Prior to joining Sciwind, Dr. Zhong was the founder, CEO, and Chief Scientific Officer of Terns Pharmaceuticals, where he led the company to build a world-class product pipeline for NASH and liver fibrosis and to become publicly listed on NASDAQ (“TERN”) in less than 4 years from its inception.

Prior to founding Terns, Dr. Zhong was the global head of Antiviral Research at Novartis and Senior Director and head of HBV/HCV/liver fibrosis discovery research at Gilead Sciences. During the early part of his career, Dr. Zhong held research leadership positions of increasing responsibilities at Valeant Pharmaceuticals, Schering-Plough Research Institute, and SmithKline Beecham. Dr. Zhong received his Ph.D. in Biochemistry from the University of Wisconsin-Madison and did postdoctoral research at University of California-San Francisco.